Works about PROTEIN kinase inhibitors


Results: 2887
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49

    Association Between Baseline Disease Characteristics and Relapse-Free Survival (RFS) in Patients (pts) with BRAF V600--Mutant Resected Stage III Melanoma Treated with Adjuvant Dabrafenib (D) + Trametinib (T) or Placebo (PBO).

    Published in:
    Journal of Oncology Navigation & Survivorship, 2019, v. 10, n. 11, p. 500
    By:
    • Schadendorf, Dirk;
    • Dummer, Reinhard;
    • Hauschild, Axel;
    • Santinami, Mario;
    • Atkinson, Victoria;
    • Mandalà, Mario;
    • Chiarion-Sileni, Vanna;
    • Larkin, James;
    • Nyakas, Marta;
    • Dutriaux, Caroline;
    • Haydon, Andrew;
    • Mortier, Laurent;
    • Robert, Caroline;
    • Schachter, Jacob;
    • Ortmann, Christine-Elke;
    • de Jong, Egbert;
    • Gasal, Eduard;
    • Kefford, Richard;
    • Kirkwood, John M.;
    • Long, Georgina V.
    Publication type:
    Article
    50